Literature DB >> 20716020

Update on non-viral delivery methods for cancer therapy: possibilities of a drug delivery system with anticancer activities beyond delivery as a new therapeutic tool.

Yasufumi Kaneda1.   

Abstract

IMPORTANCE OF THE FIELD: Cancer is the most formidable human disease. Owing to the heterogeneity of cancer, a single-treatment modality is insufficient for the complete elimination of cancer cells. Therapeutic strategies from various aspects are needed for cancer therapy. These therapeutic agents should be carefully selected to enhance multiple therapeutic pathways. Non-viral delivery methods have been utilized to enhance the tumor-selective delivery of therapeutic molecules, including proteins, synthetic oligonucleotides, small compounds and genes. AREAS COVERED IN THIS REVIEW: As non-viral delivery methods, liposomes and polymer-based delivery materials to target tumors mainly by systemic delivery, physical methods including electroporation, sonoporation, and so on, to locally inject therapeutic molecules, and virosomes to use the viral infectious machinery for the delivery of therapeutic molecules are summarized. WHAT THE READER WILL GAIN: This article aims to provide an overview of the characteristic properties of each non-viral vector. It will be beneficial to utilize appropriately the vector for cancer treatment. TAKE HOME MESSAGE: Efficient and minimally invasive vectors are generally considered to be the ideal drug delivery system (DDS). However, against cancer, DDS equipped with antitumor activities may be a therapeutic choice. By combining therapeutic molecules with DDS having antitumor activities, enhancement of the multiple therapeutic pathways may be achieved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20716020     DOI: 10.1517/17425247.2010.510511

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  16 in total

1.  Contactless magneto-permeabilization for intracellular plasmid DNA delivery in-vivo.

Authors:  Thomas J Kardos; Dietmar P Rabussay
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

2.  Targeted therapy by gene transfer of a monovalent antibody fragment against the Met oncogenic receptor.

Authors:  Elisa Vigna; Giovanni Pacchiana; Cristina Chiriaco; Simona Cignetto; Lara Fontani; Paolo Michieli; Paolo M Comoglio
Journal:  J Mol Med (Berl)       Date:  2013-09-07       Impact factor: 4.599

3.  The Effects of Negative Elements in Environment and Cancer on Female Reproductive System.

Authors:  Jiangxue Qu; Yuehan Li; Shujie Liao; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Tumor cell-targeted delivery of nanoconjugated oligonucleotides in composite spheroids.

Authors:  Kyle Carver; Xin Ming; Rudy L Juliano
Journal:  Nucleic Acid Ther       Date:  2014-12       Impact factor: 5.486

5.  Inactivated Sendai virus strain Tianjin induces apoptosis in breast cancer MCF-7 cells by promoting caspase activation and Fas/FasL expression.

Authors:  Li-Ying Shi; Zhe Han; Xiao-Xia Li; Mei Li; Han Han; Jun Chen; Sitao Zang
Journal:  Cancer Biother Radiopharm       Date:  2014-12-17       Impact factor: 3.099

Review 6.  Intracellular transport of recombinant adeno-associated virus vectors.

Authors:  M Nonnenmacher; T Weber
Journal:  Gene Ther       Date:  2012-02-23       Impact factor: 5.250

Review 7.  Physical non-viral gene delivery methods for tissue engineering.

Authors:  Adam J Mellott; M Laird Forrest; Michael S Detamore
Journal:  Ann Biomed Eng       Date:  2012-10-26       Impact factor: 3.934

8.  Activation of microbubbles by low-level therapeutic ultrasound enhances the antitumor effects of doxorubicin.

Authors:  Shuang Yang; Pan Wang; Xiaobing Wang; Xiaomin Su; Quanhong Liu
Journal:  Eur Radiol       Date:  2014-08-06       Impact factor: 5.315

9.  An RNA Molecule Derived From Sendai Virus DI Particles Induces Antitumor Immunity and Cancer Cell-selective Apoptosis.

Authors:  Li-Wen Liu; Tomoyuki Nishikawa; Yasufumi Kaneda
Journal:  Mol Ther       Date:  2015-11-09       Impact factor: 11.454

10.  Peptide-mediated Cell and In Vivo Delivery of Antisense Oligonucleotides and siRNA.

Authors:  Peter Järver; Thibault Coursindel; Samir El Andaloussi; Caroline Godfrey; Matthew Ja Wood; Michael J Gait
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-12       Impact factor: 10.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.